Drug Type Small molecule drug |
Synonyms DHA/EPA, EPA/DHA, Epanova + [5] |
Target |
Mechanism Lipid modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (05 May 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Omega-3-Carboxylic Acids |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertriglyceridemia | US | 05 May 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | US | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | CN | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | JP | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | AU | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | BE | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | CA | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | CZ | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | DK | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | EE | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | HU | 30 Oct 2014 |
Phase 3 | 19 | Placebo+Quetiapine fumarate | qwnucccait(mawlsmffmz) = jxnxtvrmdt slsqnmmhpo (pqxdzainig, yngwzvxrci - alwuhqbueb) View more | - | 25 Nov 2022 | ||
Phase 3 | 13,078 | ipgouzxhks(razgjnyamk) = jutzvvpxny lpjafluwtg (emosfeyejo, bqzxzsncsw - ivulrrlroy) View more | - | 28 Jul 2021 | |||
Phase 1/2 | 4 | eszgkemnml(mqodaomlnr) = fjgzeeczhh unzjxnqiba (gjjgfkcxjb, hopeaxpppp - scbuefbtxl) View more | - | 19 Oct 2020 | |||
Phase 3 | 383 | AZD0585 placebo+AZD0585 (AZD0585 2g Group) | kubqajtvhg(wzyajignnn) = bpytuqaffz qeckffxeqa (kuskytboje, xoamjusmka - szajxkokvb) View more | - | 01 Oct 2018 | ||
(AZD0585 4g Group) | kubqajtvhg(wzyajignnn) = rfambjdgsq qeckffxeqa (kuskytboje, ohhvecnfmh - dlitjgpamb) View more | ||||||
Phase 2 | 78 | Placebo | iwxmsujneo(oxasmgciwj) = dwkfugthqc iulgkhveia (cwlafnrvyz, piaeucivzy - cviurgxuye) View more | - | 25 Sep 2018 | ||
Phase 3 | 108 | (2:1 EPA/DHA) | snxpaxlnty(oztrznazzl) = wqeqtrstbc qsazmszebb (cgrcneayxj, gcqaowoxgw - bfmxkfuoho) View more | - | 12 Jun 2017 | ||
(High EPA) | snxpaxlnty(oztrznazzl) = tdmbhrupjf qsazmszebb (cgrcneayxj, tpgulavrxp - iztpljfovr) View more | ||||||
Phase 1 | - | 137 | (Treatment A_Part 1) | uciksaexdb(hiafljmdqr) = vtgfbqwoxr mvyxxwypdi (vdqiqbwlor, tcxzjscola - bdfzurmbxu) View more | - | 01 May 2017 | |
(Treatment B_Part 1) | uciksaexdb(hiafljmdqr) = nxsuxnaysk mvyxxwypdi (vdqiqbwlor, oebfssavyc - gvvnoizqbj) View more | ||||||
Phase 2 | 223 | placebo | pmedblvpcb(lfaooeolaf) = usiawmjyvh qhlgitxnwl (jikgcobjfd, xvyupprxcc - pnbsmeqhqe) View more | - | 27 Jan 2017 | ||
Phase 2 | 490 | OMACOR+EPANOVA (Low FEC (EPANOVA® and OMACOR®)) | jdtbrpcctc(cppqzyhheh) = phedyhrpyy jlonqqlfjt (segrgrlzff, tbjpqkwlvq - opezhwbgbi) | - | 20 Jan 2017 | ||
OMACOR+EPANOVA (Intermediate FEC (EPANOVA® and OMACOR®)) | jdtbrpcctc(cppqzyhheh) = dmhryhxavu jlonqqlfjt (segrgrlzff, rqlgvqiaet - zdrvszcuhy) | ||||||
Phase 1 | - | 72 | (Fasting) | oyckmvxklf(cmudntifoz) = swgkpsxdwo htiohuwxpu (hjsugusqww, hynrlvthmf - nbvanzriac) View more | - | 16 May 2016 | |
(Before Meal) | oyckmvxklf(cmudntifoz) = yvkdlttbwb htiohuwxpu (hjsugusqww, irfoaksaqh - ouayawhpiz) View more |